Finally a trailer for this!
And it looks like it’s been worth the wait!
Continue reading “The First Footage From Arrival is Here, and It Looks Incredible” »
And honestly, even if this isn’t an Alien Structure of some kind, it won’t be long before we DO spot some form of alien mega-structure somewhere in this galaxy of ours. I wouldn’t be surprised to find out that we ALREADY have, but mistook it for a natural structure of some kind.
The leading natural explanation for the ‘alien megastructure’ star has been discredited, leaving ET as a viable possibility.
1™, the world’s first commercial interplanetary mining mission, will fly to and rendezvous with a near-Earth asteroid to determine its value as a source of space resources. The destination asteroid will be chosen from a group of top candidates selected by the world renowned team of asteroid experts at Deep Space Industries.
Once the spacecraft arrives at the asteroid, the autonomous spacecraft will map the surface and subsurface, taking visual and infrared imagery and mapping overall water content. With the initial science campaign complete, Prospector-1 will use its water thrusters to gently touch down on the asteroid, measuring the target’s geophysical characteristics.
Prospector-1 is a small spacecraft that strikes the ideal balance between cost and performance. In addition to radiation-tolerant payloads and avionics, all DSI spacecraft notably use the Comet line of water propulsion systems, which expel superheated water vapor to generate thrust. Water will be the first asteroid mining product, so using water as propellant will provide future DSI spacecraft with the ability to refuel in space.
“Waves of virtual reality and augmented reality startups have their funding. Venture capitalists invested $1.7 billion in the AR/VR sector in the 12 months ended March 2016, and $1.2 billion of that was invested in the first quarter of this year alone, according to Digi-Capital.”
“These days every company is a tech company, but some have better niches, faster growth, more attractive offerings or more favorable share prices than others.”
With only 9 days left on the SENS cancer fundraiser here is an article from Fightaging! that explains why finding novel solutions to treating cancer is critical in the roadmap to longer healthier lives.
This year’s SENS rejuvenation research crowdfunding event puts the spotlight on the SENS Research Foundation’s cancer program. So far more than 300 people have donated, and more than $26,000 has been raised; with ten days left to go, it won’t take that much more of an effort to reach the same number of donors and the same level of support given to last year’s fundraiser, and which led to the success in that research program. As for all of the SENS research initiatives in the science of aging, the SENS Research Foundation’s work on cancer aims to support a big, bold goal in medicine: to build a single type of therapy that can be used to effectively treat all forms of cancer. When achieved, that will greatly increase the pace of progress towards control of cancer, the goal of finally ending cancer as a threat to health. At present the cancer research community spends much of its time and funding on approaches that are highly specific to only one or only a few of the hundred of subtypes of cancer. That is no way to win any time soon, as even with the vast funding devoted to cancer research, there are just too many forms of cancer and too few researchers. What is needed is to change the strategy, to focus on approaches to the treatment of cancer that are no more expensive to develop, but that far more patients can benefit from.
The most promising approach to a universal cancer therapy is to block telomere lengthening in cancerous tissues. Telomeres are a part of the mechanism that limits cell division in all human cells other than stem cells, repeating DNA sequences at the ends of chromosomes that shorten every time a cell divides. In order to achieve unfettered growth all cancers must bypass this limit by continually lengthening their telomeres, a goal that is achieved through mutations that allow cancer cells to use telomerase or the alternative lengthening of telomeres (ALT) processes. If both telomerase and ALT can be blocked in cancer tissue, then the cancer will wither; this is such a fundamental piece of cellular machinery that there is no expectation that cancer cells could find a way around it. Block only one of these two methods of telomere lengthening, however, and the cancer will probably switch to use the other. This has been observed in mice.
Now, there is a question that must be asked when it comes to atheletes and CRISPR. As we have seen over the years with doping/ atheletic enhancing drugs, etc. how will we know for sure that an athelete from China, Russia, or even US was not enhanced as an embryo with CRISPR to be a superior athelete? Sure we can claim to set up a world wide database; however, in lile all things done before not everyone plays by the rules.
The future of sport, and how technology and genetics may change it, and the lesson for business.
